Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16925236 | 0.93 | PTPN11 (0.81) | PTPN11KCNH2 | |
| SCHEMBL20032851 | 0.90 | PTPN11 (0.82) | PTPN11KCNH2 | |
| SCHEMBL20032871 | 0.90 | PTPN11 (0.83) | PTPN11 | |
| SCHEMBL20032877 | 0.89 | PTPN11 (0.83) | PTPN11 | |
| SCHEMBL20032864 | 0.87 | PTPN11 (0.87) | PTPN11 | |
| SCHEMBL16914336 | 0.86 | PTPN11 (0.66) | PTPN11KCNH2 | |
| SCHEMBL20032875 | 0.85 | PTPN11 (0.81) | PTPN11KCNH2 | |
| SCHEMBL16914374 | 0.84 | PTPN11 (0.65) | PTPN11KCNH2 | |
| SCHEMBL16925345 | 0.84 | PTPN11 (0.65) | PTPN11KCNH2 | |
| SCHEMBL20032854 | 0.84 | PTPN11 (0.75) | PTPN11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180201623-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-07-19 | — | — | US | disclosed |
| US-9938295-B2 | — | — | 2018-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201623-A1 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN7 | PTPN11 13/4885KCNH2 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.